Literature DB >> 19491327

Sustained morphine treatment augments capsaicin-evoked calcitonin gene-related peptide release from primary sensory neurons in a protein kinase A- and Raf-1-dependent manner.

Suneeta Tumati1, Henry I Yamamura, Todd W Vanderah, William R Roeske, Eva V Varga.   

Abstract

Studies have shown that long-term (5alpha,6alpha)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol (morphine) treatment increases the sensitivity to painful heat stimuli (thermal hyperalgesia). The cellular adaptations contributing to sustained morphine-mediated pain sensitization are not fully understood. It was shown previously (J Neurosci 22:6747-6755, 2002) that sustained morphine exposure augments pain neurotransmitter [such as calcitonin gene-related peptide (CGRP)] release in the dorsal horn of the spinal cord in response to the heat-sensing transient receptor potential vanilloid 1 receptor agonist 8-methyl-N-vanillyl-6-nonenamide (capsaicin). In the present study, we demonstrate that sustained morphine-mediated augmentation of CGRP release from isolated primary sensory dorsal root ganglion neurons is dependent on protein kinase A and Raf-1 kinase. Our data indicate that, in addition to neural system adaptations, sustained opioid agonist treatment also produces intracellular compensatory adaptations in primary sensory neurons, leading to augmentation of evoked pain neurotransmitter release from these cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19491327      PMCID: PMC2729797          DOI: 10.1124/jpet.109.151704

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.402


  40 in total

Review 1.  Vanilloid (Capsaicin) receptors and mechanisms.

Authors:  A Szallasi; P M Blumberg
Journal:  Pharmacol Rev       Date:  1999-06       Impact factor: 25.468

2.  Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance.

Authors:  S K Sharma; W A Klee; M Nirenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

3.  The capsaicin receptor: a heat-activated ion channel in the pain pathway.

Authors:  M J Caterina; M A Schumacher; M Tominaga; T A Rosen; J D Levine; D Julius
Journal:  Nature       Date:  1997-10-23       Impact factor: 49.962

Review 4.  Nociception and TRP Channels.

Authors:  Mitsuko Numazaki; Makoto Tominaga
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2004-12

5.  Further confirmation of the role of adenyl cyclase and of cAMP-dependent protein kinase in primary afferent hyperalgesia.

Authors:  Y O Taiwo; J D Levine
Journal:  Neuroscience       Date:  1991       Impact factor: 3.590

6.  Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance.

Authors:  T W Vanderah; L R Gardell; S E Burgess; M Ibrahim; A Dogrul; C M Zhong; E T Zhang; T P Malan; M H Ossipov; J Lai; F Porreca
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

7.  A proinflammatory chemokine, CCL3, sensitizes the heat- and capsaicin-gated ion channel TRPV1.

Authors:  Ning Zhang; Saadet Inan; Sadeet Inan; Alan Cowan; Ronghua Sun; Ji Ming Wang; Thomas J Rogers; Michael Caterina; Joost J Oppenheim
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-11       Impact factor: 11.205

8.  Opiate-dependent modulation of adenylate cyclase.

Authors:  S K Sharma; W A Klee; M Nirenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1977-08       Impact factor: 11.205

9.  Prostaglandins facilitate peptide release from rat sensory neurons by activating the adenosine 3',5'-cyclic monophosphate transduction cascade.

Authors:  C M Hingtgen; K J Waite; M R Vasko
Journal:  J Neurosci       Date:  1995-07       Impact factor: 6.167

10.  The mu opioid agonist morphine modulates potentiation of capsaicin-evoked TRPV1 responses through a cyclic AMP-dependent protein kinase A pathway.

Authors:  Irina Vetter; Bruce D Wyse; Gregory R Monteith; Sarah J Roberts-Thomson; Peter J Cabot
Journal:  Mol Pain       Date:  2006-07-16       Impact factor: 3.395

View more
  7 in total

1.  Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance.

Authors:  T M Largent-Milnes; T Yamamoto; P Nair; J W Moulton; V J Hruby; J Lai; F Porreca; T W Vanderah
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

2.  Intrathecal PKA-selective siRNA treatment blocks sustained morphine-mediated pain sensitization and antinociceptive tolerance in rats.

Authors:  S Tumati; W R Roeske; T M Largent-Milnes; T W Vanderah; E V Varga
Journal:  J Neurosci Methods       Date:  2011-05-06       Impact factor: 2.390

3.  Sustained morphine treatment augments prostaglandin E2-evoked calcitonin gene-related peptide release from primary sensory neurons in a PKA-dependent manner.

Authors:  Suneeta Tumati; William R Roeske; Todd W Vanderah; Eva V Varga
Journal:  Eur J Pharmacol       Date:  2010-09-15       Impact factor: 4.432

4.  Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA.

Authors:  S Tumati; W R Roeske; T Largent-Milnes; R Wang; T W Vanderah; E V Varga
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

5.  Intrathecal delivery of farnesyl thiosalicylic acid and GW 5074 attenuates hyperalgesia and allodynia in chronic constriction injury-induced neuropathic pain in rats.

Authors:  Amteshwar Singh Jaggi; Nirmal Singh
Journal:  Neurol Sci       Date:  2012-03-02       Impact factor: 3.830

Review 6.  The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse.

Authors:  Willem Sebastiaan van Hoogstraten; Antoinette MaassenVanDenBrink
Journal:  J Headache Pain       Date:  2019-05-16       Impact factor: 7.277

7.  GluN2B N-methyl-D-aspartate receptor and excitatory amino acid transporter 3 are upregulated in primary sensory neurons after 7 days of morphine administration in rats: implication for opiate-induced hyperalgesia.

Authors:  Kerui Gong; Aditi Bhargava; Luc Jasmin
Journal:  Pain       Date:  2016-01       Impact factor: 7.926

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.